How we’re leveraging our technology to help find solutions for the long-term impact of COVID-19

About Caladrius

Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease.

News

October 8, 2020
Caladrius Biosciences Opens Study of CLBS119 to Repair COVID-19-Induced Lung Damage

October 7, 2020
Caladrius Biosciences to Present at the Alliance for Regenerative Medicine’s Virtual Cell and Gene Meeting on the Mesa

October 6, 2020
Caladrius Biosciences to Present at the BIO Investor Forum Digital

Events

September 1, 2020
LD Micro 500 Virtual Conference

August 13, 2020
Caladrius Biosciences Second Quarter 2020 Financial Results and Business Update Conference Call

June 5, 2020
BioNJ COVID-19 Rapid Fire Research Showcase

Sign up to our e-mail list to receive Caladrius announcements.

Technologies & Capabilities

CD34 Cell Technology

T Regulatory Cell Technology